Why the study?
Direct-current cardioversion for persistent symptomatic AF is often supported by antiarrhythmic drugs to improve outcomes, and ranolazine has shown evidence of antiarrhythmic properties despite primarily being used as an antianginal agent.
Does ranolazine improve rhythm control in patients with persistent atrial fibrillation?
Does ranolazine improve rhythm control in patients with persistent atrial fibrillation?
Ranolazine may have beneficial antiarrhythmic effects for rhythm control in persistent atrial fibrillation, both as monotherapy and in combination with class III antiarrhythmic drugs.
Answers are grounded in this paper and cite their sources.
May facilitate cardioversion in persistent AF; hypothesis-generating and requires controlled trials before practice consideration.
BACKGROUND: Direct-current cardioversion (DCCV) is used as a rhythm-control strategy in persistent symptomatic atrial fibrillation (AF) and is often supported by antiarrhythmic drugs (AADs), usually class III AADs, to improve outcomes. Although primarily used as an antianginal agent, ranolazine has also shown evidence of antiarrhythmic properties in AF. CASES: We detail cases where ranolazine was used as an AAD for persistent AF: 6 patients who chemically cardioverted on ranolazine monotherapy and 4 patients on combination therapy with ranolazine and a class III AAD (2 chemical cardioversions and 2 successful DCCVs) who had previously failed DCCV on a class III AAD. DISCUSSION: These cases demonstrate ranolazine's beneficial antiarrhythmic effects, both as a single agent and in combination with a class III AAD. This raises the possibility that ranolazine could play a greater role in persistent AF management and merits further investigation in randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Presslie et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: